Soterix Medical Inc. (SMI) was formed to develop and deploy innovative medical treatments focused on neuropsychiatric and neurological disorders and rehabilitation. Founded in 2008, SMI is the world leader in clinical trials for non-invasive neuromodulation working with over 250 medical centers in the US and worldwide. SMI has licensed and developed a comprehensive intellectual property portfolio that includes High-Definition transcranial Direct Current Stimulation (HD-tDCS), Limited Total Energy tDCS (LTE-tDCS), and Neurotargeting. From the most targeted non-invasive clinical systems to the most portable units, Soterix Medical provides clinicians and patients with unique and adaptable solutions. Ongoing Phase I, II, IIb, and III trials use investigational devices that are regulated/limited by US or Federal law. SMI is proudly based in New York City with international distributors in all major markets.

Engineering Serving Humanity

At Soterix Medical, Engineering Serving Humanity means that we are committed to bring the most advanced medical technology into the hands of people who need it. The commitment underpins everything we do.

The intent of this 1-day intensive workshop is to familiarize participants with the fundamentals of the theoretical and practical aspects of transcranial Direct Current Stimulation (tDCS) and High-Definition transcranial Direct Current Stimulation (HD-tDCS). Preceding the hands-on demonstration and break-out sessions, the day begins with lectures by pioneers in the field of tDCS who will provide a general background on tDCS mechanisms and protocols including live demonstration of tDCS. Issues related to dose decision, safety, regulatory compliance, and best clinical practices will be introduced.

At Soterix Medical Inc., Engineering Serving Humanity means that we're committed to bring the most advanced medical technology into the hands of people who need it. The commitment underpins everything we do.